Based on the MAGLE CHEMOSWED HOLDING stock forecast from 0 analysts, the average analyst target price for MAGLE CHEMOSWED HOLDING is not available over the next 12 months. MAGLE CHEMOSWED HOLDING’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of MAGLE CHEMOSWED HOLDING is Slightly Bullish , which is based on 6 positive signals and 3 negative signals. At the last closing, MAGLE CHEMOSWED HOLDING’s stock price was EUR 2.78. MAGLE CHEMOSWED HOLDING’s stock price has changed by +0.00% over the past week, +3.73% over the past month and +26.36% over the last year.
No recent analyst target price found for MAGLE CHEMOSWED HOLDING
No recent average analyst rating found for MAGLE CHEMOSWED HOLDING
Company Overview MAGLE CHEMOSWED HOLDING
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants for multiple indications; melperone hydrochloride, which is an antipsychotic agent; isradipine, a calcium channel blocker used to treat hypertension; amantadine sulfate that is used in the treatment of central nervous system disorders; and benserazide hydrochloride, which is used in combination with L-Dopa in the treatment of Parkinson's disease. The company also offers EmboCept S, a microsphere-based medical device used in vascular occlusion of liver and lung tumors; SmartGel, a non-allergenic hydrogel based on the company's microsphere technology; and SmartPAN, a medical device for the detection of pancreatic fluid leakage during open or minimally invasive surgical procedures. In addition, it is developing EmboCept M for the treatment of benign prostatic hyperplasia; EmboCept L for the treatment of uterine fibroids; SmartGel II, an advanced wound care hydrogel for the removal and prevention of wound biofilm; and SmartBone, an advanced formulation of microspheres in combination with active ingredients for stimulation of bone growth in surgical implant procedures. The company was founded in 1944 and is based in Malmö, Sweden. Magle Chemoswed Holding AB (publ) is a subsidiary of Magle AB. Read Less
Magle Chemoswed Holding AB (publ), together with its subsidiaries, operates as a contract development and manufacturing organization that serves pharmaceutical and medical device industry on a contract basis in Sweden. It provides warfarin sodium products used as anticoagulants f...Read More
Frequently Asked Questions About MAGLE CHEMOSWED HOLDING (52X:F) Stock
Stock Target Advisor's fundamental analysis for MAGLE CHEMOSWED HOLDING's stock is Slightly Bullish .
Unfortunately we do not have enough data on 52X:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 52X:F's stock to indicate what its average analyst target is.
52X:F stock's Price/Earning ratio is 19.86.
Our analysis grades 52X:F stock's Price / Earning ratio at F. This means that 52X:F stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the F exchange.
Based on this 52X:F may be a overvalued for its sector.
The last closing price of 52X:F's stock was EUR 2.78.
The most recent market capitalization for 52X:F is EUR 0.05B.
Unfortunately we do not have enough analyst data on 52X:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MAGLE CHEMOSWED HOLDING's stock.
As per our most recent records MAGLE CHEMOSWED HOLDING has 147 Employees.
MAGLE CHEMOSWED HOLDING's registered address is AgneslundsvAegen 27, Malmö, Sweden, 212 15.
You can get more information about it from MAGLE CHEMOSWED HOLDING's website at https://www.maglechemoswed.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About MAGLE CHEMOSWED HOLDING (52X:F) Stock
Stock Target Advisor's fundamental analysis for MAGLE CHEMOSWED HOLDING's stock is Slightly Bullish .
Unfortunately we do not have enough data on 52X:F's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on 52X:F's stock to indicate what its average analyst target is.
52X:F stock's Price/Earning ratio is 19.86.
Our analysis grades 52X:F stock's Price / Earning ratio at F. This means that 52X:F stock's Price/Earning ratio is above 51% of the stocks in the Biotechnology sector in the F exchange.
Based on this 52X:F may be a overvalued for its sector.
The last closing price of 52X:F's stock was EUR 2.78.
The most recent market capitalization for 52X:F is EUR 0.05B.
Unfortunately we do not have enough analyst data on 52X:F's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains MAGLE CHEMOSWED HOLDING's stock.
As per our most recent records MAGLE CHEMOSWED HOLDING has 147 Employees.
MAGLE CHEMOSWED HOLDING's registered address is AgneslundsvAegen 27, Malmö, Sweden, 212 15.
You can get more information about it from MAGLE CHEMOSWED HOLDING's website at https://www.maglechemoswed.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 52X:F !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
